GS030

Asset

Optogenetic gene therapy encoding a channelrhodopsin to restore light sensitivity in retinal ganglion cells

Stage
Phase 1
Modality
Gene therapy
Target
Not known
1
Indication
0
Trials
1
Developer

Indications

1

In the full profile

  • Owner and partners2
  • Competitors1
  • Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets